• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性移植物功能障碍。

Primary graft dysfunction.

机构信息

Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Perelman School of Medicine.

Division of Cardiovascular Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

出版信息

Curr Opin Organ Transplant. 2021 Jun 1;26(3):321-327. doi: 10.1097/MOT.0000000000000876.

DOI:10.1097/MOT.0000000000000876
PMID:33938469
Abstract

PURPOSE OF REVIEW

Primary graft dysfunction (PGD) is a devastating complication in the acute postoperative lung transplant period, associated with high short-term mortality and chronic rejection. We review its definition, pathophysiology, risk factors, prevention, treatment strategies, and future research directions.

RECENT FINDINGS

New analyses suggest donation after circulatory death and donation after brain death donors have similar PGD rates, whereas donors >55 years are not associated with increased PGD risk. Recipient pretransplant diastolic dysfunction and overweight or obese recipients with predominant abdominal subcutaneous adipose tissue have increased PGD risk. Newly identified recipient biomarkers and donor and recipient genes increase PGD risk, but their clinical utility remains unclear. Mixed data still exists regarding cold ischemic time and PGD risk, and increased PGD risk with cardiopulmonary bypass remains confounded by transfusions. Portable ex vivo lung perfusion (EVLP) may prevent PGD, but its use is limited to a handful of centers. Although updates to current PGD treatment are lacking, future therapies are promising with targeted therapy and the use of EVLP to pharmacologically recondition donor lungs.

SUMMARY

There is significant progress in defining PGD and identifying its several risk factors, but effective prevention and treatment strategies are needed.

摘要

目的综述

原发性移植物功能障碍(PGD)是急性肺移植术后的一种严重并发症,与短期高死亡率和慢性排斥反应有关。我们回顾了其定义、发病机制、危险因素、预防、治疗策略和未来的研究方向。

最新发现

新的分析表明,循环死亡后捐献者和脑死亡后捐献者的 PGD 发生率相似,而 >55 岁的捐献者与 PGD 风险增加无关。移植前受者舒张功能障碍和超重或肥胖受者,以腹部皮下脂肪组织为主,PGD 风险增加。新发现的受者生物标志物和供者及受者基因增加了 PGD 风险,但它们的临床应用尚不清楚。关于冷缺血时间和 PGD 风险的混合数据仍然存在,体外膜肺氧合(ECMO)的使用增加与输血有关,仍存在 PGD 风险。便携式体外肺灌注(EVLP)可能预防 PGD,但由于需要输血,其应用仅限于少数中心。尽管目前缺乏更新的 PGD 治疗方法,但靶向治疗和使用 EVLP 对供肺进行药物调理的未来治疗方法很有前景。

总结

在定义 PGD 和确定其几个危险因素方面取得了重大进展,但仍需要有效的预防和治疗策略。

相似文献

1
Primary graft dysfunction.原发性移植物功能障碍。
Curr Opin Organ Transplant. 2021 Jun 1;26(3):321-327. doi: 10.1097/MOT.0000000000000876.
2
Extended post-ex vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: Results from a multicentric study.延长的离体肺后灌注冷保存预测原发性移植物功能障碍和死亡率:一项多中心研究的结果。
J Heart Lung Transplant. 2020 Sep;39(9):954-961. doi: 10.1016/j.healun.2020.05.002. Epub 2020 May 16.
3
Cell-free DNA in human ex vivo lung perfusate as a potential biomarker to predict the risk of primary graft dysfunction in lung transplantation.人体肺体外灌洗液中的游离 DNA 作为预测肺移植中原发性移植物功能障碍风险的潜在生物标志物。
J Thorac Cardiovasc Surg. 2021 Aug;162(2):490-499.e2. doi: 10.1016/j.jtcvs.2020.08.008. Epub 2020 Aug 11.
4
Primary graft dysfunction: pathophysiology to guide new preventive therapies.原发性移植肝无功能:指导新型预防疗法的病理生理学
Expert Rev Respir Med. 2017 Feb;11(2):119-128. doi: 10.1080/17476348.2017.1280398. Epub 2017 Jan 20.
5
Soluble Adhesion Molecules During Ex Vivo Lung Perfusion Are Associated With Posttransplant Primary Graft Dysfunction.体外肺灌注期间的可溶性黏附分子与移植后原发性移植物功能障碍相关。
Am J Transplant. 2017 May;17(5):1396-1404. doi: 10.1111/ajt.14160. Epub 2017 Feb 1.
6
Incidence and severity of primary graft dysfunction after lung transplantation using rejected grafts reconditioned with ex vivo lung perfusion.使用体外肺灌注对废弃移植物进行再处理后肺移植中原发性移植物功能障碍的发生率和严重程度。
Eur J Cardiothorac Surg. 2014 Nov;46(5):789-93. doi: 10.1093/ejcts/ezu239. Epub 2014 Jul 24.
7
Primary Graft Dysfunction.原发性移植物功能障碍。
Semin Respir Crit Care Med. 2021 Jun;42(3):368-379. doi: 10.1055/s-0041-1728794. Epub 2021 May 24.
8
Pretransplant dyslipidaemia influences primary graft dysfunction after lung transplantation.移植前血脂异常会影响肺移植后的原发性移植物功能障碍。
Interact Cardiovasc Thorac Surg. 2016 Apr;22(4):402-5. doi: 10.1093/icvts/ivv295. Epub 2015 Dec 30.
9
The Perioperative Lung Transplant Virome: Torque Teno Viruses Are Elevated in Donor Lungs and Show Divergent Dynamics in Primary Graft Dysfunction.围手术期肺移植病毒组:细小病毒在供体肺中升高,并在原发性移植功能障碍中表现出不同的动态变化。
Am J Transplant. 2017 May;17(5):1313-1324. doi: 10.1111/ajt.14076. Epub 2016 Nov 4.
10
Donor and recipient risk factors for the development of primary graft dysfunction following lung transplantation.肺移植后原发性移植物功能障碍发展的供体和受者危险因素。
Front Immunol. 2024 Feb 6;15:1341675. doi: 10.3389/fimmu.2024.1341675. eCollection 2024.

引用本文的文献

1
Donor lung weight a novel predictor for primary graft dysfunction.供体肺重量:原发性移植肺功能障碍的一种新型预测指标。
JHLT Open. 2025 Apr 30;9:100271. doi: 10.1016/j.jhlto.2025.100271. eCollection 2025 Aug.
2
Biomarkers for primary graft dysfunction after lung transplantation: a review of current evidence and future prospects.肺移植术后原发性移植肺功能障碍的生物标志物:当前证据与未来展望综述
Front Physiol. 2025 May 22;16:1557182. doi: 10.3389/fphys.2025.1557182. eCollection 2025.
3
FLRT3 Overexpression Attenuates Ischemia-Reperfusion Induced Vascular Hyperpermeability and Lung Injury Through RND3.
FLRT3过表达通过RND3减轻缺血再灌注诱导的血管通透性增加和肺损伤。
Lung. 2025 Mar 6;203(1):39. doi: 10.1007/s00408-025-00791-w.
4
Contrasting predictors of severe primary graft dysfunction following transplant for chronic and acute respiratory failure.慢性和急性呼吸衰竭移植后严重原发性移植物功能障碍的对比预测因素。
J Thorac Dis. 2024 Aug 31;16(8):5050-5062. doi: 10.21037/jtd-24-100. Epub 2024 Aug 28.
5
Early serum biomarkers to characterise different phenotypes of primary graft dysfunction after lung transplantation: a systematic scoping review.用于表征肺移植后原发性移植功能障碍不同表型的早期血清生物标志物:一项系统的范围综述
ERJ Open Res. 2024 Aug 5;10(4). doi: 10.1183/23120541.00121-2024. eCollection 2024 Jul.
6
New therapeutic concepts against ischemia-reperfusion injury in organ transplantation.器官移植中对抗缺血再灌注损伤的新治疗概念。
Expert Rev Clin Immunol. 2023 Jul-Dec;19(10):1205-1224. doi: 10.1080/1744666X.2023.2240516. Epub 2023 Jul 28.
7
Contemporary trends in PGD incidence, outcomes, and therapies.当代 PGD 发生率、结局和治疗的趋势。
J Heart Lung Transplant. 2022 Dec;41(12):1839-1849. doi: 10.1016/j.healun.2022.08.013. Epub 2022 Aug 31.